Healthcare / Medical Care FacilitiesNYSE
$87.09
-5.45 (-5.89%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-148.9M · quality 63.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
42/100
C
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.5B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-308.8%
↓Gross Margin
-2.7%
↓Debt/Equity
0.29
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2019–2025 · 6 años de histórico normalizado
Revenue CAGR
+39.8%
FCF CAGR
—
FCF margin
-2.5%
FCF / Net income
0.38x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $5.93B · net income $-391.3M · FCF $-148.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | $5.93B | $5.93B | $6.06B | $4.32B | $2.39B | $1.52B | $1.22B | $794.4M |
| Net Income | $-391.3M | $-391.3M | $-260.2M | $-262.6M | $-106.6M | $-406.5M | $-60.1M | $-282.6M |
| EBITDA | $-368.9M | $-368.9M | $-218.2M | $-167.6M | $-72.4M | $-357.6M | $-42.6M | $-65.2M |
| EPS | -23.75 | -23.75 | -15.75 | -16.00 | -6.50 | — | — | — |
| Gross Margin | -2.7% | -2.7% | 0.1% | 1.6% | 4.7% | — | — | — |
| Operating Margin | -7.2% | -7.2% | -4.8% | -5.4% | -4.4% | -24.5% | -4.7% | -13.4% |
| Net Margin | -6.6% | -6.6% | -4.3% | -6.1% | -4.5% | -26.7% | -4.9% | -35.6% |
| Balance Sheet | ||||||||
| Debt/Equity | 0.29 | 0.29 | 0.09 | 0.07 | 0.05 | 0.04 | -0.23 | — |
| Current Ratio | 1.04 | 1.04 | — | — | — | — | — | — |
| Cash Flow | ||||||||
| Free Cash Flow | $-148.9M | $-148.9M | $-99.1M | $-187.0M | $-163.5M | $-154.7M | $-55.0M | $-106.8M |
| Returns | ||||||||
| ROE | -308.8% | -308.8% | -55.2% | -39.7% | -10.2% | -37.2% | 21.1% | — |
| Valuation | ||||||||
| P/B | 11.38 | 11.38 | 1.82 | 5.33 | 6.03 | — | — | — |
| Growth & Yield | ||||||||
| Revenue Growth | -2.1% | -2.1% | 40.4% | 80.7% | — | 24.9% | 53.4% | — |
| EPS Growth | -50.8% | -50.8% | 1.6% | -146.2% | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+54.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-15.75 → -23.75
Residual
+54.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.